Rhenman & Partners Asset Management AB Buys Horizon Bancorp (IN), HCA Healthcare Inc, Regeneron Pharmaceuticals Inc, Sells Horizon Therapeutics PLC, Array BioPharma Inc, Allergan PLC

Stockholm, V7, based Investment company Rhenman & Partners Asset Management AB (Current Portfolio) buys Horizon Bancorp (IN), HCA Healthcare Inc, Regeneron Pharmaceuticals Inc, Alexion Pharmaceuticals Inc, Stemline Therapeutics Inc, sells Horizon Therapeutics PLC, Array BioPharma Inc, Allergan PLC, Cigna Corp, Walgreens Boots Alliance Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Rhenman & Partners Asset Management AB. As of 2019Q2, Rhenman & Partners Asset Management AB owns 88 stocks with a total value of $908 million. These are the details of the buys and sells.

For the details of Rhenman & Partners Asset Management AB's stock buys and sells, go to https://www.gurufocus.com/guru/rhenman+%26+partners+asset+management+ab/current-portfolio/portfolioportfolio

These are the top 5 holdings of Rhenman & Partners Asset Management AB
  1. Vertex Pharmaceuticals Inc (VRTX) - 185,232 shares, 3.74% of the total portfolio. Shares added by 28.28%
  2. Humana Inc (HUM) - 105,000 shares, 3.07% of the total portfolio. Shares added by 36.36%
  3. Jazz Pharmaceuticals PLC (JAZZ) - 187,171 shares, 2.94% of the total portfolio.
  4. Alexion Pharmaceuticals Inc (ALXN) - 203,017 shares, 2.93% of the total portfolio. Shares added by 48.77%
  5. Horizon Bancorp (IN) (HBNC) - 1,087,656 shares, 2.88% of the total portfolio. New Position
New Purchase: Horizon Bancorp (IN) (HBNC)

Rhenman & Partners Asset Management AB initiated holding in Horizon Bancorp (IN). The purchase prices were between $15.51 and $17.13, with an estimated average price of $16.17. The stock is now traded at around $15.99. The impact to a portfolio due to this purchase was 2.88%. The holding were 1,087,656 shares as of .

New Purchase: HCA Healthcare Inc (HCA)

Rhenman & Partners Asset Management AB initiated holding in HCA Healthcare Inc. The purchase prices were between $112.01 and $135.18, with an estimated average price of $126.22. The stock is now traded at around $140.57. The impact to a portfolio due to this purchase was 2.03%. The holding were 136,164 shares as of .

New Purchase: Stemline Therapeutics Inc (STML)

Rhenman & Partners Asset Management AB initiated holding in Stemline Therapeutics Inc. The purchase prices were between $12.9 and $16.1, with an estimated average price of $14.45. The stock is now traded at around $13.21. The impact to a portfolio due to this purchase was 0.83%. The holding were 493,999 shares as of .

New Purchase: HMS Holdings Corp (HMSY)

Rhenman & Partners Asset Management AB initiated holding in HMS Holdings Corp. The purchase prices were between $27.64 and $32.83, with an estimated average price of $30.54. The stock is now traded at around $33.32. The impact to a portfolio due to this purchase was 0.36%. The holding were 100,000 shares as of .

New Purchase: Intercept Pharmaceuticals Inc (ICPT)

Rhenman & Partners Asset Management AB initiated holding in Intercept Pharmaceuticals Inc. The purchase prices were between $77.77 and $120.68, with an estimated average price of $89.45. The stock is now traded at around $67.05. The impact to a portfolio due to this purchase was 0.33%. The holding were 37,600 shares as of .

New Purchase: Viking Therapeutics Inc (VKTX)

Rhenman & Partners Asset Management AB initiated holding in Viking Therapeutics Inc. The purchase prices were between $7.67 and $10.63, with an estimated average price of $8.55. The stock is now traded at around $8.22. The impact to a portfolio due to this purchase was 0.27%. The holding were 291,499 shares as of .

Added: Regeneron Pharmaceuticals Inc (REGN)

Rhenman & Partners Asset Management AB added to a holding in Regeneron Pharmaceuticals Inc by 181.34%. The purchase prices were between $299.6 and $414.82, with an estimated average price of $332.61. The stock is now traded at around $296.52. The impact to a portfolio due to this purchase was 1%. The holding were 45,014 shares as of .

Added: Alexion Pharmaceuticals Inc (ALXN)

Rhenman & Partners Asset Management AB added to a holding in Alexion Pharmaceuticals Inc by 48.77%. The purchase prices were between $113.68 and $141.3, with an estimated average price of $128.81. The stock is now traded at around $122.32. The impact to a portfolio due to this purchase was 0.96%. The holding were 203,017 shares as of .

Added: Vertex Pharmaceuticals Inc (VRTX)

Rhenman & Partners Asset Management AB added to a holding in Vertex Pharmaceuticals Inc by 28.28%. The purchase prices were between $164.61 and $190.37, with an estimated average price of $174.67. The stock is now traded at around $174.08. The impact to a portfolio due to this purchase was 0.82%. The holding were 185,232 shares as of .

Added: Humana Inc (HUM)

Rhenman & Partners Asset Management AB added to a holding in Humana Inc by 36.36%. The purchase prices were between $232.89 and $276.48, with an estimated average price of $253.55. The stock is now traded at around $282.19. The impact to a portfolio due to this purchase was 0.82%. The holding were 105,000 shares as of .

Added: FibroGen Inc (FGEN)

Rhenman & Partners Asset Management AB added to a holding in FibroGen Inc by 83.35%. The purchase prices were between $35.13 and $55.53, with an estimated average price of $43.71. The stock is now traded at around $47.76. The impact to a portfolio due to this purchase was 0.79%. The holding were 347,439 shares as of .

Added: Eli Lilly and Co (LLY)

Rhenman & Partners Asset Management AB added to a holding in Eli Lilly and Co by 62.12%. The purchase prices were between $110.79 and $129.32, with an estimated average price of $117.71. The stock is now traded at around $107.27. The impact to a portfolio due to this purchase was 0.75%. The holding were 160,000 shares as of .

Sold Out: Horizon Therapeutics PLC (HZNP)

Rhenman & Partners Asset Management AB sold out a holding in Horizon Therapeutics PLC. The sale prices were between $22.81 and $28.48, with an estimated average price of $25.35.

Sold Out: Array BioPharma Inc (ARRY)

Rhenman & Partners Asset Management AB sold out a holding in Array BioPharma Inc. The sale prices were between $20.84 and $46.58, with an estimated average price of $27.97.

Sold Out: Allergan PLC (AGN)

Rhenman & Partners Asset Management AB sold out a holding in Allergan PLC. The sale prices were between $115.73 and $167.43, with an estimated average price of $138.45.

Sold Out: Walgreens Boots Alliance Inc (WBA)

Rhenman & Partners Asset Management AB sold out a holding in Walgreens Boots Alliance Inc. The sale prices were between $49.34 and $63.49, with an estimated average price of $53.16.

Sold Out: Celgene Corp (CELG)

Rhenman & Partners Asset Management AB sold out a holding in Celgene Corp. The sale prices were between $92.35 and $98.91, with an estimated average price of $94.95.

Sold Out: AbbVie Inc (ABBV)

Rhenman & Partners Asset Management AB sold out a holding in AbbVie Inc. The sale prices were between $65.7 and $83.98, with an estimated average price of $78.61.



Here is the complete portfolio of Rhenman & Partners Asset Management AB. Also check out:

1. Rhenman & Partners Asset Management AB's Undervalued Stocks
2. Rhenman & Partners Asset Management AB's Top Growth Companies, and
3. Rhenman & Partners Asset Management AB's High Yield stocks
4. Stocks that Rhenman & Partners Asset Management AB keeps buying